Timing of CMV-specific effector memory T cells predicts viral replication and survival after allogeneic hematopoietic stem cell transplantation

Transplant International

Volumn 27, Issue 12, 2014, Pages 1253-1262

  Espigado, Ildefonso ^a   De La Cruz Vicente, Fátima ^a   Benmarzouk Hidalgo, Omar J ^a   Gracia Ahufinger, Irene ^a   Garcia Lozano, Jose R ^a   Aguilar Guisado, Manuela ^a   Cisneros, Jose M ^a   Urbano Ispizua, Alvaro ^a   Perez Romero, Pilar ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

allogeneic stem cell transplantation; cytomegalovirus infection; cytomegalovirus specific immune response

Indexed keywords

CYCLOSPORIN; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID; VALGANCICLOVIR; ANTIVIRUS AGENT; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL SURFACE; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; MALE; MEMORY T LYMPHOCYTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS SURVIVAL; ALLOGRAFT; CYTOMEGALOVIRUS INFECTIONS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDY; T LYMPHOCYTE SUBPOPULATION; TIME; VIREMIA; VIRUS ACTIVATION; YOUNG ADULT;

ADOLESCENT; ADULT; ALLOGRAFTS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TIME FACTORS; VIRAL LOAD; VIREMIA; VIRUS ACTIVATION; VIRUS REPLICATION; YOUNG ADULT;

EID: 84911145026     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12406     Document Type: Article

References (40)

1. Boeckh MNW, Papanicolaou G, Rubin R, Wingard JR, Zaia J,. CMV in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 5: 543.
2. Gandhi MK, Wills MR, Okecha G, et al,. Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation. Blood 2003; 102: 3427.
3. Rauser G, Einsele H, Sinzger C, et al,. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004; 103: 3565.
4. Solano C, Munoz I, Gutierrez A, et al,. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 2001; 39: 3938.
5. George MJ, Snydman DR, Werner BG, et al,. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc., Gaithersburg, Maryland. Am J Med 1997; 103: 106.
6. Gratama JW, Boeckh M, Nakamura R, et al,. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 2010; 116: 1655.
7. Ljungman P, Griffiths P, Paya C,. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
8. Ljungman P, Perez-Bercoff L, Jonsson J, et al,. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006; 91: 78.
9. Ozdemir E, Saliba RM, Champlin RE, et al,. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 2007; 40: 125.
10. Drew WL,. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. Curr Opin Infect Dis 2007; 20: 408.
11. Hakki M, Riddell SR, Storek J, et al,. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102: 3060.
12. Moins-Teisserenc H, Busson M, Scieux C, et al,. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis 2008; 198: 818.
13. Brown JA, Stevenson K, Kim HT, et al,. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood 2010; 115: 4111.
14. Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P,. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007; 40: 865.
15. Lilleri D, Gerna G, Fornara C, Lozza L, Maccario R, Locatelli F,. Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 2006; 108: 1406.
16. Solano C, Benet I, Clari MA, et al,. Enumeration of cytomegalovirus-specific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. Haematologica 2008; 93: 1434.
17. Reusser P, Riddell SR, Meyers JD, Greenberg PD,. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991; 78: 1373.
18. Sacre K, Nguyen S, Deback C, et al,. Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8+ T cells and control of HCMV replication after allogeneic stem cell transplantation. J Virol 2008; 82: 10143.
19. Ganepola S, Gentilini C, Hilbers U, et al,. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 293.
20. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C,. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255.
21. Boeckh M, Nichols WG,. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003.
22. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M,. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273.
23. Kotton CN, Kumar D, Caliendo AM, et al,. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
24. Kotton CN,. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol 2010; 6: 711.
25. Filipovich AH, Weisdorf D, Pavletic S, et al,. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945.
26. Leisenring WM, Martin PJ, Petersdorf EW, et al,. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108: 749.
27. BenMarzouk-Hidalgo OJ, Cordero E, Martin-Pena A, et al,. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection. Antivir Ther 2009; 14: 641.
28. Gracia-Ahufinger I, Tormo N, Espigado I, et al,. Differences in cytomegalovirus plasma viral loads measured in allogeneic hematopoietic stem cell transplant recipients using two commercial real-time PCR assays. J Clin Virol 2010; 48: 142.
29. BenMarzouk-Hidalgo OJ, Cisneros JM, Cordero E, et al,. Therapeutic effect of the acquisition of CMV-specific immune response during pre-emptive treatment. Transplantation 2011; 91: 927.
30. Jimenez-Velasco A, Barrios M, Roman-Gomez J, et al,. Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms. Leukemia 2005; 19: 336.
31. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC,. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176: 1484.
32. Hassan-Walker AF, Kidd IM, Sabin C, Sweny P, Griffiths PD, Emery VC,. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol 1999; 58: 182.
33. Bitmansour AD, Waldrop SL, Pitcher CJ, et al,. Clonotypic structure of the human CD4+ memory T cell response to cytomegalovirus. J Immunol 2001; 167: 1151.
34. Gamadia LE, Rentenaar RJ, van Lier RA, ten Berge IJ,. Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol 2004; 65: 486.
35. Lilleri D, Piccinini G, Genini E, et al,. Monitoring of human cytomegalovirus (HCMV)-specific CD4+ T cell frequency by cytokine flow cytometry as a possible indicator for discontinuation of HCMV secondary prophylaxis in HAART-treated AIDS patients. J Clin Virol 2004; 29: 297.
36. Pourgheysari B, Piper KP, McLarnon A, et al,. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant 2009; 43: 853.
37. Pourgheysari B, Bruton R, Parry H, et al,. The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. Blood 2010; 116: 2968.
38. Lacey SF, Gallez-Hawkins G, Crooks M, et al,. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 2002; 74: 722.
39. Peggs KS, Verfuerth S, Pizzey A, et al,. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. Biol Blood Marrow Transplant 2003; 9: 198.
40. Walter EA, Greenberg PD, Gilbert MJ, et al,. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038.